Abteilung für Kardiologie, Pneumologie und Angiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Deutsches Zentrum für Herz-Kreislauf-Forschung, Standort Heidelberg, Mannheim, Germany.
Clin Res Cardiol. 2018 Apr;107(4):271-280. doi: 10.1007/s00392-018-1202-x. Epub 2018 Feb 16.
This article about the emerging field of cardio-oncology highlights typical side effects of oncological therapies in the cardiovascular system, cardiovascular complications of malignancies itself, and potential preventive or therapeutic modalities.
We performed a selective literature search in PubMed until September 2016.
Cardiovascular events in cancer patients can be frequently attributed to oncological therapies or to the underlying malignancy itself. Furthermore, many patients with cancer have pre-existing cardiovascular diseases that can be aggravated by the malignancy or its therapy. Cardiovascular abnormalities in oncological patients comprise a broad spectrum from alterations in electrophysiological, laboratory or imaging tests to the occurrence of thromboembolic, ischemic or rhythmological events and the impairment of left ventricular function or manifest heart failure.
A close interdisciplinary collaboration between oncologists and cardiologists/angiologists as well as an increased awareness of potential cardiovascular complications could improve clinical care of cancer patients and provides a basis for an improved understanding of underlying mechanisms of cardiovascular morbidity.
本文介绍了肿瘤心脏病学这一新兴领域，重点阐述了肿瘤治疗在心血管系统中产生的典型副作用、恶性肿瘤本身引起的心血管并发症，以及潜在的预防或治疗方法。
我们在 PubMed 上进行了选择性文献检索，检索时间截至 2016 年 9 月。
癌症患者发生心血管事件的原因可能是肿瘤治疗或基础恶性肿瘤本身。此外，许多癌症患者存在预先存在的心血管疾病，这些疾病可能会因恶性肿瘤或其治疗而加重。肿瘤患者的心血管异常包括从电生理学、实验室或影像学检查的改变到血栓栓塞、缺血或节律紊乱事件的发生以及左心室功能障碍或明显心力衰竭等广泛谱。
肿瘤学家与心脏病学家/血管专家之间的密切跨学科合作，以及对潜在心血管并发症的认识提高，可改善癌症患者的临床护理，并为更好地了解心血管发病率的潜在机制提供基础。
